Condition: Prostate Cancer · Radiotherapy Side Effect · Hypofractionation · Sponsor: CHU de Quebec-Universite Laval
Phase 1-2 study, comparing ultra-hypofractionnated (UH) to a moderately hypofractionnated (MH) radiation therapy, with image guided HDR prostate brachytherapy. Using iso-equivalent doses, a non-inferiority analysis will be done in order to prove UH non-inferior to MH, toxicity wise. Acceptability, tolerability, acute and late toxicity will be reported. MRI visible dominant intra-prostatic lesion will be outlines and variability between radiation oncologists and radiologists will be reported. As secondary objective, biochemical and clinical failure free survival will be reported at 5 \& 10 years.
This description comes directly from the study's public registry record.
Andre-Guy Martin · 14186915264 · andre-guy.martin.med@ssss.gouv.qc.ca
Josee Allard · 14186915264 · josee.allard@chudequebec.ca
Always discuss trial participation with your own doctor first.
| CHUdeQuebec | Québec, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05786742